LTR PharmaASX:LTP -4.27%15 ROE % is -39.48% as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,255 Biotechnology companies, LTR Pharma ranks better than 56.25% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. LTR Pharma's annualized net income for the quarter that ended in Dec. 2025 was A$-11.52 Mil. LTR Pharma's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$29.19 Mil. Therefore, LTR Pharma's annualized ROE % for the quarter that ended in Dec. 2025 was -39.48%.
The historical rank and industry rank for LTR Pharma's ROE % or its related term are showing as below:
ASX:LTP'
s ROE % Range Over the Past 10 Years
Min: -133.36 Med: -75.67 Max: -28.97
Current: -28.97
During the past 5 years, LTR Pharma's highest ROE % was -28.97%. The lowest was -133.36%. And the median was -75.67%.
ASX:LTP's ROE % is ranked better than 56.25% of 1255
companies
in the Biotechnology industry
Industry Median: -38.18
vs ASX:LTP: -28.97
LTR Pharma (ASX:LTP) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
LTR Pharma ROE % Related Terms
LTR Pharma ROE % Historical Data
* Premium members only.
The historical data trend for LTR Pharma's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LTR Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's ROE % distribution charts can be found below:
* The bar in red indicates where LTR Pharma's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
LTR Pharma (ASX:LTP) has a ROE % of -39.48% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #549 out of 1255 companies in the Biotechnology industry, placing it in the top 43.7%.
Is LTR Pharma's ROE % too high?
LTR Pharma's current ROE % is -39.48%. Based on the distribution chart, LTR Pharma ranks #549 out of 1255 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #549 out of 1255 companies for ROE %. This puts LTR Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LTR Pharma and its competitors. LTR Pharma's current ROE % is -39.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current ROE % of -39.48%. The current ROE % is -39.48%. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current ROE % is -39.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 